shouldiuse.io

Categories

VERDICT

Fortrea Review

Depends

Should I use Fortrea?

Global CRO advancing clinical trials and drug development - fortrea.com

· 1 week ago

Fortrea fits mid-size and large biopharma sponsors outsourcing complex, multi-region clinical trials. Small studies, individual patients, or buyers expecting software and transparent pricing should not use it.

Confidence

Medium. Based on 20+ public sources; the pasted page returned only accessibility boilerplate, so findings come from reviews, news, filings, and Fortrea's own pages. Note: Fortrea is a contract research organization (services), not software.

Ratings

  • Value for moneyNo published client pricing evidence
  • Ease of useService business; no usability evidence
  • Feature depth
  • Support quality
  • Security posture

Pricing

Not disclosed

ModelNot disclosed
Monthly feesNot disclosed
HardwareNot disclosed

Best for

  • Mid-to-large biotech sponsors
  • Multi-region Phase I-IV trials
  • Sponsors wanting FSP or hybrid outsourcing
  • Complex areas: neuro, hep B, infectious disease

Not for

  • Small biotechs with one simple study
  • Patients seeking trials — that's, not this B2B arm
  • Anyone wanting software, self-serve, or public pricing
  • Buyers needing financial stability — active class action and revenue decline

Gotchas - check before you buy

high

Custom contracts only — no rate card; analysts flag strong pricing power against buyers

high

Active securities litigation — verify financial stability before multi-year trial commitments

medium

Layoff reviews claim replacements were 'cheaper, lower quality' — ask who staffs your study

medium

Portfolio churn: 2024 divestitures and 2026 acquisitions mean service lines may move

Pros and cons

Pros

  • Global full-service CRO spun off from Labcorp in 2023
  • Flexible delivery: full-service and FSP outsourcing models
  • Veeva and Advarra partnerships cover trial tech and payments
  • Acquiring Worldwide's early-phase unit adds Phase I capacity
  • Deep therapeutic content and case studies across specialties

Cons

  • Securities class action and fraud investigations filed 2024-2025
  • Analyst flags 83% stock drop, declining revenue, low margins
  • Employee approval 56-57%; layoff reviews cite cheaper replacements
  • Divested enabling services and patient access units in 2024
  • No published pricing; everything is negotiated enterprise contracting

Sources & method

- 12 sources - No known vulnerabilities found in the sources reviewed.

official x2review x4security x1news x5

Key stats

  • Feature depth: 4/5

    Rating

  • Not disclosed

    Starting price

  • 12

    Sources

  • Analyzed

  • Value for money. No published client pricing evidence
  • Ease of use. Service business; no usability evidence
  • Feature depth: 4/5. Broad services across phases, geographies, therapeutic areas
  • Support quality: 3/5. Mixed employee reviews signal uneven delivery capacity
  • Security posture: 3/5. No breaches reported; publishes cyber risk disclosure
  • 3.7/5 Glassdoor rating 865 employee reviews
  • 56-57% Employee approval Glassdoor sentiment
  • 2023 Spun off from Labcorp Independent CRO since
  • -83% Stock decline Seeking Alpha, May 2025

Pricing

Not disclosed

Security

No known vulnerabilities found in the sources reviewed.

Full analysis

Based on 20+ public sources; the pasted page returned only accessibility boilerplate, so findings come from reviews, news, filings, and Fortrea's own pages. Note: Fortrea is a contract research organization (services), not software.

Global CRO for pharma-scale clinical trials; big, pricey, litigation-dinged. Small sponsors and non-pharma buyers should look elsewhere.

Methodology

Based on 20+ public sources; the pasted page returned only accessibility boilerplate, so findings come from reviews, news, filings, and Fortrea's own pages. Note: Fortrea is a contract research organization (services), not software.

Read how a report is made.

Sources

  1. Fortrea (official site)fortrea.com
    official
  2. Glassdoor Fortrea Reviews (865)glassdoor.com
    review
  3. Indeed employee reviewsindeed.com
    review
  4. Reddit: Thoughts on Fortreareddit.com
    review
  5. Seeking Alpha: 83% price drop analysisseekingalpha.com
    news
  6. Pomerantz class action filingprnewswire.com
    news
  7. Securities fraud investigation (BusinessWire)businesswire.com
    news
  8. Fortrea-Veeva-Advarra partnershipcontractpharma.com
    news
  9. Fortrea acquires Worldwide early-phase divisionappliedclinicaltrialsonline.com
    news
  10. SEC 10-K cybersecurity disclosuresec.gov
    security
  11. Labcorp spin-off naming announcementir.labcorp.com
    official
  12. RFP.wiki CRO alternativesrfp.wiki
    review

Add this review to your site

This check for Fortrea says Depends.

Put the badge on your site.

Visitors see the independent review.

The link points here, and search engines follow it.

This is the badge visitors see on your site.

Depends Fortrea Independent review on Should I Use It

Paste one snippet. Keep the link as it is. A nofollow tag stops search engines from following it.

Rate this review

Anonymous. You can change your vote.

Loading votes…

Comments

One queue. No nested comments. Give a display name first. Limit: 200 words per comment and 7 comments per day. You can edit or delete yours.

Save a name to write a comment.

0 / 200 words

No comments yet.